PTC Therapeutics, Inc.

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Investigation Details

PTC issued a press release on May 5, 2025, “announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients.” Although “[t]he study met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels (p<0.0001) at Week 12 and favorable safety and tolerability", analysts who reviewed the data anticipated that the Company would likely need to conduct a Phase 3 study to better establish whether the treatment is actually slowing HD. Following this news, PTC's stock price fell over 18% on the same day.